Evofem Biosciences

197 articles about Evofem Biosciences

• Evofem Biosciences Announces Pricing of $50 Million Public Offering

  5/18/2021

  Company Would Receive up to an Additional $50 Million Upon Exercise of Accompanying Short-Term Warrants

• Evofem Biosciences Announces Proposed Public Offering

  5/17/2021

  Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of its common stock (or pre-funded warrants to purchase common stock in lieu of common stock) in an underwritten public offering.

• New Data on EVO100 for the Prevention of Chlamydia and Gonorrhea in Women to be Presented at ISPOR 2021

  5/17/2021

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that new research on its investigational drug EVO100 for the prevention of chlamydia and gonorrhea in women will be highlighted in a poster presentation at the annual meeting of the Professional Society for Health Economics and Outcomes Research, Virtual ISPOR 2021

• Evofem Biosciences Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women

  5/12/2021

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EVO100 for the prevention of urogenital gonorrhea in women

• Evofem Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/6/2021

  Evofem Biosciences, Inc., reported financial results for the three-month period ended March 31, 2021.

• Evofem Biosciences Announces Presentation of Two New Phexxi Data Sets at the 2021 American College of Obstetricians and Gynecologists Annual Meeting

  4/28/2021

  Evofem Biosciences, Inc., announced that two new data sets from its Phase 3 AMPOWER trial evaluating Phexxi® will be presented at the 2021 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting.

• Evofem Biosciences to Report First Quarter 2021 Results and Provide Corporate Update on Thursday, May 6, 2021

  4/22/2021

   Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the first quarter ended March 31, 2021 as follows:

• Evofem Biosciences to Deliver Keynote Address and Present Two Phexxi Data Sets at NCODA 2021 National Spring Forum

  4/21/2021

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced the company will deliver the keynote address and present two poster presentations on Phexxi® (lactic acid, citric acid, potassium bitartrate) at the upcoming NCODA 2021 National Spring Forum, which will be held April 28 to 30 as a virtual E-Meeting.

• Evofem Biosciences Announces Closing of Public Offering of Common Stock

  3/29/2021

  Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the closing of its previously announced underwritten public offering of 17,142,857 shares of its common stock at $1.75 per share.  Evofem's aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses

• Evofem Biosciences Announces Pricing of $30 Million Public Offering of Common Stock - Mar 25, 2021

  3/25/2021

  Evofem Biosciences, Inc. announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a price to the public of $1.75 per share.

• Evofem Biosciences Announces Proposed Public Offering of Common Stock - Mar 24, 2021

  3/24/2021

  Evofem Biosciences, Inc. announced that it intends to offer and sell, subject to market and other conditions, $30 million of shares of its common stock in an underwritten public offering.

• Evofem Biosciences' DTC Campaign & Get Phexxi Delivers Strong Initial Impact

  3/17/2021

  - Over 2,400 Phexxi units dispensed in February 2021, up 30% from prior month - - Accelerating retail demand drove 73% increase in ex-factory sales month-over-month - - Ex-factory sales YTD 2021 through mid-March have exceeded FY 2020 levels -

• Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention

  3/16/2021

   Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology (AJOG). This double-blinded, placebo-controlled, multicenter study of EVO100 met its primary and secondary efficacy endpoints

• Evofem Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

  3/4/2021

  Evofem Biosciences, Inc., a commercial stage biopharmaceutical company, reported financial results for the three- and twelve-month periods ended December 31, 2020.

• Evofem Biosciences to Present at H.C. Wainwright Global Life Sciences Conference

  2/23/2021

   Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the upcoming H.C. Wainwright Global Life Sciences Conference. Evofem's CEO, Saundra Pelletier , will provide an update on the commercialization of its non-hormonal, use-it-only-when-you-need-it birth control method,

• Evofem Biosciences to Report Fourth Quarter and Year-End 2020 Results and Provide Corporate Update on Thursday, March 4, 2021

  2/18/2021

  -- Conference Call Scheduled for 4:30 p.m. ET -- -- Company to Provide Update on Commercial Launch of Phexxi and Pivotal Phase 3 Trial of EVO100 --

• Evofem Biosciences Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of Phexxi®, A Non-Hormonal Birth Control Option for Women

  2/16/2021

  Marketing campaign includes the brand's first-ever commercial spot introducing women to a birth control that puts them in control of their body, their sex life, and their pregnancy prevention.

• Evofem Biosciences and NCODA Announce Collaboration to Educate Oncology Community about Phexxi®, A Non-Hormonal Birth Control Option for Women with Cancer

  2/4/2021

  Evofem Biosciences, Inc., (NASDAQ: EVFM) and NCODA (National Community Oncology Dispensing Association, Inc.), are launching a collaboration to positively impact the quality of life for female patients living with, fighting and recovering from cancer by raising awareness about the importance and availability of a new non-hormonal birth control method, Phexxi®

• Evofem Biosciences Wins Business Intelligence Group's BIG Innovation Award 2021

  1/12/2021

  Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi®

• Evofem Biosciences to Participate in Medicaid National Drug Rebate Program for Phexxi® Effective January 1, 2021

  12/22/2020

   Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it has entered into an agreement with the U.S. Centers for Medicare and Medicaid Services (CMS) to participate in the Medicaid National Drug Rebate Program (NDRP), providing access to Phexxi® (lactic acid, citric acid and potassium bitartrate) for the Medicaid population effective January 1, 2021.